Lonza and Triumvira Immunologics ("Triumvira") announced that the first patient has been dosed with Triumvira's investigational T-cell antigen coupler (TAC-T cell) adoptive immunotherapy, TAC01-HER2, in development for the treatment of HER2-overexpressing cancers. Triumvira's TAC01-HER2, which harnesses natural T cell activation, was manufactured on Lonza's proprietary Cocoon® Platform at C3i Center Inc in Montréal, Canada. The Cocoon® Platform is an automated and closed platform for patient-scale cell therapy manufacturing, designed to overcome manufacturing challenges associated with patient-scale personalized medicines.
This collaboration aims to bring novel immunotherapies to patients for the treatment of HER2-overexpressing cancers. The Cocoon® Platform will enable manufacturing efficiencies, robustness, and cost reductions by decreasing the necessary manpower, time, and space requirements and ultimately allow the delivery of potentially curative cellular immunotherapies to more patients, at a higher quality and for a reduced cost. From the start of the collaboration, Triumvira's TAC-T cell treatment was efficiently translated to Lonza's Cocoon® Platform, involving technology transfer to C3i and engineering runs, to support an investigational new drug (IND) submission in under a year.
Eytan Abraham, Vice President Personalized Medicine, Lonza, commented: "Treating the first HER2-overexpressing cancer patient at MD Anderson with Triumvira's therapy demonstrates the potential of the Cocoon® Platform to manufacture therapies at third party manufacturing sites using a decentralized model. The fact that the timeline for moving a fully automated manufacturing process to IND submission using the Cocoon® Platform at a new manufacturing site was less than a year demonstrates the ability to truly accelerate timelines from lab to clinic using the Cocoon® Platform. Our goal remains to enable partners to provide personalized immunotherapies at a lower cost, higher quality, and more quickly to critically ill patients."
Paul Lammers, President and CEO, Triumvira, added: "We're proud to be the first company in the US to dose a patient with a cell therapy manufactured on the Cocoon® Platform, which is an innovative and elegant solution that addresses challenges of manufacturing autologous cell therapies. Our proprietary TAC-T technology combined with Lonza's manufacturing expertise enables us to deliver a high-quality and truly personalized cell therapy and manufacturing process that may one day be used at the point-of-care. We look forward to our continued partnership with Lonza and C3i as we move forward with the clinical trial of TAC01-HER2."
Louisa Petropoulos, CEO, C3i, commented: "C3i Center Inc. is founded on the principle that Canadian breakthroughs in cell and gene therapy for serious diseases like cancer should remain in Canada for the benefit of our health and economy. Experimental treatments like TAC01-HER2 won't become a reality unless we can produce and refine cells quickly, reliably and affordably, and that is what an automated closed system like the Cocoon® Platform brings to the table. We are thrilled to put the Cocoon® Platform to the test as part of our suite of cutting-edge technologies as we support this critical clinical trial."
The TAC01-HER2 clinical trial is actively enrolling patients across numerous clinical study sites in the US. More information on Triumvira's pipeline and programs can be found at www.triumvira.com and details on this clinical trial can be found at clinicaltrials.gov using ClinicalTrials.gov Identifier NCT04727151.
Lonza is the preferred global partner to the pharmaceutical, biotech and nutrition markets. We work to enable a healthier world by supporting our customers to deliver new and innovative medicines that help treat a wide range of diseases. We achieve this by combining technological insight with world-class manufacturing, scientific expertise and process excellence. Our unparalleled breadth of offerings enables our customers to commercialize their discoveries and innovations in the healthcare sector.
Founded in 1897 in the Swiss Alps, today, Lonza operates across five continents. With approximately 15,000 full-time employees, we comprise high-performing teams and individual talent that make a meaningful difference to our own business, as well as to the communities in which we operate. The company generated sales of CHF 2.5 billion with a CORE EBITDA of CHF 847 million in H1 2021. Find out more at www.lonza.com.
About Triumvira Immunologics
Triumvira Immunologics, Inc. ("Triumvira") is a clinical-stage company developing unique, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with liquid and solid tumors. Our proprietary T cell Antigen Coupler (TAC) technology is a robust and versatile platform that activates natural T cell functions differently from cell therapies such as CAR-T and engineered T cell receptor (TCR) therapies. Triumvira is headquartered in Austin, Texas with research facilities in Hamilton, Ontario.
About the C3i Center Inc (C3i)
C3i Center Inc. is a unique Canadian organization that accelerates the development of cancer immunotherapies and cellular therapies by providing a one-stop-shop for commercialization across the continuum of product development. C3i merges research expertise with business savvy and word-class technology to move potential products through the "valley of death" to where they can attract enough private-sector investment to succeed. C3i operations in Montreal, Quebec as well as an office in Toronto, Ontario.
www.CentreC3i.com / Twitter @C3i_Montreal
Additional Information and Disclaimer
Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.
Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.
These press releases may also interest you